Allergan plc (AGN)

NYSE - NYSE Real Time Price. Currency in USD
221.62-0.37 (-0.17%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close221.99
Bid221.71 x 200
Ask221.80 x 300
Day's Range220.38 - 224.91
52wk Range195.50 - 322.68
1y Target EstN/A
Market Cap87.75B
P/E Ratio (ttm)21.10
Avg Vol (3m)3,301,864
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • The Wall Street Journal2 hours ago

    [$$] Unity Biotechnology, in Battle Against Aging, Raises $116M

    After operating in stealth for about four years while studying ways to turn back the clock on diseases of aging in animals, now it has fresh capital to do the same thing in humans.

  • Can Allergan (AGN) Keep the Earnings Streak Alive in Q3?
    Zacks4 hours ago

    Can Allergan (AGN) Keep the Earnings Streak Alive in Q3?

    Allergan plc (AGN) will be reporting third-quarter 2016 earnings on Nov 2, before market open. Last quarter, the company delivered a positive earnings surprise of 2.13%.

  • American City Business Journals5 hours ago

    Allergan to acquire Boston drug company for $200M

    Allergan has announced it will acquire Boston-based Motus Therapeutics for $200 million. Motus, a wholly-owned subsidiary of Rhythm Holding Co. which also owns Rhythm Pharmaceuticals, is focused on developing peptide therapeutics for gastrointestinal disease. Allergan (AGN) previously paid $47 million for the option to acquire Motus, funding that also went to support Phase 2b clinical trials.